PDS Biotechnology/$PDSB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About PDS Biotechnology
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.
Ticker
$PDSB
Sector
Primary listing
Employees
24
Headquarters
Website
PDSB Metrics
BasicAdvanced
$55M
-
-$0.91
0.95
-
Price and volume
Market cap
$55M
Beta
0.95
52-week high
$3.92
52-week low
$0.85
Average daily volume
396K
Financial strength
Current ratio
2.918
Quick ratio
2.764
Long term debt to equity
81.36
Total debt to equity
116.147
Interest coverage (TTM)
-6.36%
Profitability
EBITDA (TTM)
-34.208
Effective tax rate (TTM)
3.10%
Management effectiveness
Return on assets (TTM)
-42.42%
Return on equity (TTM)
-156.16%
Valuation
Price to book
3.48
Price to tangible book (TTM)
3.48
Price to free cash flow (TTM)
-1.392
Free cash flow yield (TTM)
-71.86%
Free cash flow per share (TTM)
-0.855
Growth
Earnings per share change (TTM)
-24.95%
3-year earnings per share growth (CAGR)
-2.03%
What the Analysts think about PDSB
Analyst ratings (Buy, Hold, Sell) for PDS Biotechnology stock.
PDSB Financial Performance
Revenues and expenses
PDSB Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for PDS Biotechnology stock?
PDS Biotechnology (PDSB) has a market cap of $55M as of August 26, 2025.
What is the P/E ratio for PDS Biotechnology stock?
The price to earnings (P/E) ratio for PDS Biotechnology (PDSB) stock is 0 as of August 26, 2025.
Does PDS Biotechnology stock pay dividends?
No, PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next PDS Biotechnology dividend payment date?
PDS Biotechnology (PDSB) stock does not pay dividends to its shareholders.
What is the beta indicator for PDS Biotechnology?
PDS Biotechnology (PDSB) has a beta rating of 0.95. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.